Journal Articles
2020

COVID-19 and Cancer Patients.
R Patel
Northwell Health

J Park
Northwell Health

A Shah
Northwell Health

MW Saif
Zucker School of Medicine at Hofstra/Northwell, wsaif@northwell.edu

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Oncology Commons

Recommended Citation
Patel R, Park J, Shah A, Saif M. COVID-19 and Cancer Patients.. . 2020 Jan 01; 3(1):Article 6349 [ p.].
Available from: https://academicworks.medicine.hofstra.edu/articles/6349. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic
Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara
Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

HHS Public Access
Author manuscript
Author Manuscript

Cancer Med J. Author manuscript; available in PMC 2020 May 13.
Published in final edited form as:
Cancer Med J. 2020 ; 3(1): 40–48.

COVID-19 and Cancer Patients
Rajvi Patel, Jennifer Park, Ankit Shah, Muhammad Wasif Saif*
Department of Medical Oncology, Northwell Health Cancer Institute, Donald and Barbara Zucker
School of Medicine at Hofstra and Feinstein Institute for Medical Research, USA

Abstract
Author Manuscript

COVID-19 has now been declared a global pandemic with evolving incidence rates and fatalities.
It is important to identify vulnerable populations who will be impacted most by this pandemic
leading to higher mortality rates compared to the general healthy population. Although older
patients and patients with co-morbidities fall into this vulnerable group, patients with hematologic
and oncologic malignancies on active cytotoxic treatments are at even greater risk as they are both
myelosuppressed and immunosuppressed. In addition to following the universal guidelines
recommended by the Centers for Disease Control (CDC), it is important to also institute guidelines
for cancer centers to help protect this vulnerable population. We review the current data, risks, and
recommendations for COVID-19 in cancer patients.
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Introduction
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The World Health Organization (WHO) recently declared COVID-19 to be a public health
emergency of international concern due to its rapid spread. As of March 20, 2020, there are
255,811 reported cases, 10,495 deaths, and 89,918 recovered. This new virus, named 2019nCoV by WHO is a new human-infecting Betacoronavirus that likely originated from
chrysanthemum bats based on its genetic similarly to two bat-derived SARS-like
coronaviruses [1]. This virus was first observed in Wuhan, China in December 2019. The
virus enters the host cell using its densely glycosylated spike (S) protein, binding with high
affinity to the angiotensin-converting enzyme 2 (ACE2) receptor which is expressed in type
II alveolar cells, affecting the lung and airways thus causing a respiratory illness [1]. Patients
with cancer are overall more susceptible to infection given their immunocompromised state
due to malignancy and anticancer treatments such as chemotherapy, radiation, or surgery.
Therefore, these patients may be at increased risk for contracting COVID-19 and subsequent
poor prognosis.
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The disease can spread from person to person through small droplets from the nose or mouth
that may spread when a person coughs or sneezes. Another mode of transmission is by
touching a surface that the droplets have landed on and then touching their eye, nose, or
mouth. Incubation period ranges from 1 to 14 days with a median of 5 days −6 days
although 24 days was reported in one study [1]. Symptoms can be mild to severe and can
include fever, cough, and shortness of breath. Other symptoms may include body aches,
nasal congestion, sore throat, or diarrhea. It is important recognize that some people who are
infected may not develop any symptoms. There fore patients can present with varying
degrees of illness but data from China show that primary symptoms were fever (87%), cough
(67.8%), sputum production (34%), myalgias (14%), sore throat (13%) and diarrhea (3.8%)
[1]. Chest radiographs showed bilateral patchy infiltrates and ground glass opacities on CT
scan in 56.4% of patients though these studies were interpreted as normal in 17.9% of nonsevere cases and 2.9% of severe cases. Lymphopenia was seen in 83.2%, prolonged
prothrombin time in 58% and elevated lactate dehydrogenase in 40% of patients [1].
The role of molecular evolution of the virus from population genetic analysis looking at 103
SARS-CoV-2 genomes showed that these viruses evolved into two major types: the S type
(~30%) was evolutionarily older and less aggressive and the L-type (~70%) which was more
prevalent during the initial outbreak in Wuhan that demonstrated quick spread and
aggressive behavior [2]. The molecular evolution in cancer patients has yet to be
investigated.

Testing for COVID-19
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SARS-COV-2 is the etiologic agent of COVID-19. Its viral nucleic acid is detected using
real-time polymerase chain reaction (RT-PCR) and is considered the reference standard for
the diagnosis [3]. Specimens should be obtained from saliva, upper respiratory tract such as
nasopharyngeal and oropharyngeal swabs, lower respiratory tract, e.g. sputum, endotracheal
aspirate, or bronchoalveolar lavage, urine and stool if possible [3]. In some cases, repeated
testing may be required to confirm the diagnosis. If the SARS-COV-2 nucleic acid is not
detected in respiratory tract samples taken on two consecutive occasions at least 24 hours
apart, COVID-19 can be ruled out. It is to be noted that serology, as a diagnostic procedure,
should be used only if RT-PCR is not available [3].
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Other organisms responsible to cause respiratory infections, such as influenza virus A and B,
adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, SARS-CoV,
bacterial pneumonia, chlamydia, etc. should also be ruled out if clinically indicated. One
should consider collecting blood cultures for bacteria that may cause pneumonia and sepsis
before initiating antimicrobial therapy. It is also important to recognize key differentiating
features between coronavirus, influenza, and allergies (Table 1).
A computed tomography (CT) scan of the chest without contrast is the most useful
diagnostic tool to confirm or rule out viral pneumonia, and should be performed in suspected
cases. In a recent report, sensitivity of chest CT in diagnosing COVID-19 was shown to be
greater than that of RT-PCR (98% vs. 71%) [4].
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Who is at highest risk for complications with COVID-19 infection?
As COVID-19 is still a relatively new disease and epidemiologic data is still emerging, there
is limited data regarding which patients are at higher risk for complications. Preliminary
recommendations from the CDC suggest the following groups are at higher risk for serious
illness and should follow guidelines listed in (Table 2) [5,6].
•

Older adults age >60.

•

Patients with chronic medical conditions such as: Heart disease, lung disease,
and diabetes.

This list is likely not comprehensive, however, and it is reasonable to assume that those at
highest risk for complications of coronavirus are similar to those with influenza infection
including the following additional groups:
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•

Patients that are immunocompromised either due to underlying disorder or those
on chronic immunosuppressive therapy:
–

HIV/AIDS

–

Recent bone marrow transplanto

–

Bone marrow failure disorderso

–

Leukemia or Lymphoma

–

Other cancers currently receiving chemotherapy.

–

Those on chronic immunosuppressive therapy including chronic
steroids for history of solid organ transplant or autoimmune illness.

Author Manuscript

•

Pregnant women or those immediately postpartum (<2 weeks).

•

Patients with other chronic medical conditions such as end stage renal disease,
neuromuscular disorders, sickle cell disease, and cirrhosis.

•

Patients who reside in nursing homes or long-term care facilities.

While children <2 years of age are typically considered a higher risk group in influenza
infection, limited data thus far suggest COVID-19 appears to cause milder infection in
children [7].

COVID-19 infection during pregnancy
Author Manuscript

Cancer and pregnancy, though uncommon, does exist simultaneously in patients. Moreover,
caretakers and healthcare providers who are pregnant can be exposed to COVID-19 as well.
Literature suggests some risk of premature rupture of membranes, preterm delivery, fetal
tachycardia and fetal distress when the infection occurs in the third trimester of pregnancy.
However, data on transplacental transmission is scarce and available data only comprises of
amniotic fluid, cord blood, neonatal throat swab, and breast milk samples available from six
of the nine patients who were found to be negative for SARS-COV-2. Similarly, at this time
we do not know about the vaginal shedding of virus [8].
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Why are cancer patients at a higher risk for complications?
Patients with cancer are at a higher risk in general because of myelosuppressive effects of
treatment and their disease, which suppresses their immune system. Myelosuppression or
bone marrow suppression is defined as a decrease in the ability of the bone marrow to
produce blood cells. This may results in decreased red blood cells (anemia), white blood
cells (leukopenia), and platelets (thrombocytopenia). Myelosuppression may occur when the
stem cells in the bone marrow are damaged either by chemotherapy, by crowding of tumor
cells or fibrosis, or due to bone marrow failure [9]. Therefore in setting of myelosuppression
there will be immunosuppression since the production of white blood cells is decreased.
However, immunosuppression does not always mean myelosuppression. For example, a
medication may suppress white blood cells or other parts of immune system but not affect
the red blood cells or platelets.
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The two main types of cells in our immune sy other cancers and currently stem consist of
neutrophils and lymphocytes.
•

Neutrophils defend against bacterial or fungal infection and they are usually the
first responders to microbial infection [10,11].

•

Lymphocytes fall into three categories [10,11]:
–

B-cells make antibodies that can bind to pathogens to block pathogen
invasion and activate the complement system to enhance pathogen
destruction.

–

T-cells:
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–

♦

CD4+ helper cells bind antigenic peptides presented on major
histocompatibility complex (MHC) class II molecules on
antigen presenting cells and produce cytokines to help
coordinate the immune response.

♦

CD8+ cytotoxic cells bind antigens presented on MHC-I
complex of virus-infected cells and kill them.

Natural killer cells are able to kill cells of the body that do not display
MHC class-I molecules.
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It is important to recognize that in addition to underlying malignancy and cytotoxic agents,
COVID-19 infection in itself also causes lymphopenia, which further weakens the immune
system. Therefore, if cancer patients getting chemotherapy agents that cause lymphopenia
develop infection with COVID-19, then they may develop severe lymphopenia resulting in
higher mortality rates. Cyclophosphamide, cisplatin, methotrexate, fludarabine, and taxanes
are among the most myelosuppressive agents known to induce lymphopenia [12]. Other
targeted agents known to cause lymphopenia include: mammalian target of rapamycin
(mTOR) inhibitors and tyrosine-kinase receptor inhibitors targeting vascular endothelial
growth factor receptor (VEGFR) [13,14]. Additionally, the combination of chemotherapy
and immunotherapy may also induce severe lymphopenia [13].
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A previous analysis of influenza-infected individuals requiring hospitalization suggested that
patients with lung cancer and adult hematologic malignancies had longer length of stay,
higher rates of mechanical ventilation, and higher case-fatality rates compared to patients
with other malignancies hospitalized for influenza [15]. In general, patients with aggressive
hematologic malignancies, such as acute leukemia or high-grade myelodysplastic syndrome,
and bone marrow transplant recipients are felt to be at highest risk for infectious
complications [15].
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Patients with lung cancer represent another high-risk group as they are at increased risk for
pulmonary complications from respiratory viruses. This increased risk may be due to altered
anatomy and/or presence of concomitant smoking-related lung disease. Patients receiving
cytotoxic chemotherapy for other solid tumor malignancies are also at increased risk for
complications, though this risk is heterogeneous, depending on the extent of their disease
and the anticipated bone marrow suppression of their specific chemotherapy regimen [16].
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One study in China examined a prospective cohort of 18 laboratory confirmed COVID-19
patients who had a history of cancer [16]. Lung adenocarcinoma was the most frequent type
of malignancy followed by colorectal, urothelial, breast, and others. 25% of cancer patients
with COVID-19 had received chemotherapy or surgery within the past month while 25%
were cancer survivors in routine follow up after primary resection [16]. Compared to the
patients without cancer, the cancer patients with COVID-19 were older (mean age 63 years
versus 47-year-old), more likely to have a history of smoking, more polypnea and had more
severe baseline CT manifestations. Patients with cancer were observed to be at highest risk
for severe events, defined as the composite of admission to the intensive care unit requiring
invasive ventilation or death, and cancer was associated with a shorter time to development
of severe events when compared to non-cancer patients [16]. Among patients with cancer,
older age was the only risk factor for severe events. Patients with lung cancer did not have a
higher probability of severe events compared with other cancer types and there were no
significant differences in sex, other baseline symptoms, comorbidities or baseline severity of
x-ray findings, though sample size was small making comparative analyses difficult.
In contrast, patients receiving single agent immunotherapy and endocrine-based therapies
have a lower risk given lack of bone marrow suppression from these modalities. Lastly,
patients with remote history of cancer and those who are believed to be in remission are
anticipated to have a complication risk approaching that of the general population.
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Case fatality rate (CFR), similar to disease illness, seems to be highly variable but increased
in patients with medical comorbidities and those who developed severe respiratory
symptoms. In non-cancer patients, CFR was suggested to be as high as 8% to 15% within
the Hubei Province, though outside of Hubei, the CFR was no higher than 1% – 2%. Patients
with cancer were observed to have a higher risk and shorter time to development of severe
events that included death especially if they underwent chemotherapy or surgery within the
past month [1]. Therefore, it is extremely important to prevent infection with COVID-19 in
this very vulnerable patient population with hematologic and oncologic malignancies on
active chemotherapy. See guidelines for cancer centers listed in (Table 3).
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How to manage cancer patients during this pandemic?
We recommend more intensive screening and surveillance in cancer patients for signs and
symptoms of COVID-19 infection. If the patient is found to be infected with COVID-19,
cancer treatment should be postponed as long as possible if the patient’s disease status is
stable.
As previously discussed, there is concern that treatments such as chemotherapy or
immunotherapy will cause further immunosuppression and myelosuppression causing severe
events including death. Ontario guidelines recommend dividing cancer patients into priority
classification groups (Table 4). Below are the treatment recommendations based on the
priority classification groups A, B, or C as per the Ontario Health Pandemic Planning
Clinical Guideline for Patients with Cancer [17].
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•

Patients already on treatment should continue therapy if possible.

•

Patients in Priority A group should be treated.

•

Waiting lists should be created for Priority B patients requiring treatment and
should be contacted by a triage nurse to discuss and arrange treatment as soon as
feasible. Treatment can be deferred for up to several weeks.

•

Patients should be given a telephone number to call in the event their condition
changes.

•

Discussion with the patient should take place regarding the risks and benefits of
delaying the initiation of treatment in addition to increased risk of contracting an
infection if patient becomes immunocompromised by cancer treatment.
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Currently, treatments for COVID-19 infected patients are largely supportive. WHO and its
partners are launching international clinical trials that aim to generate robust data from
around the world to find the most effective treatments for COVID-19. There is some
preliminary data that suggests therapeutic effects of hydroxychloroquine in combination
with azithromycin to reduce both the duration and symptoms of COVID-19 infection [18].
Vaccine clinical trials have been initiated as well. There is another trial exploring the
efficacy of lopinavir-ritonavir in patients with COVID-19 infection [19]. This trial was a
randomized, open-label trial involving 199 hospitalized adult patients with confirmed
COVID-19 infection who were randomized 1:1 to receive lopinavir-ritonavir twice daily for
14 days in addition to standard care versus standard care alone. The primary end point was
time to clinical improvement or discharge from the hospital [19].
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99 patients were assigned to lopinavir-ritonavir group and 100 patients to standard of care
group. Unfortunately, this was a negative trial where treatment with lopinavir-ritonavir was
not associated with a difference from standard of care in terms of time to clinical
improvement (hazard ratio 1.24, 95% confidence interval 0.90 to 1.72). In addition,
mortality at 28 days was similar in both groups as well [19]. There are no known studies to
date on the efficacy and toxicity of the investigational COVID-19 therapeutics in cancer
patients and further studies are needed to determine efficacy in cancer patients.
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Differentiation between coronavirus, influenza and allergies.
Coronavirus

Fever
Cough
Shortness of breath or difficulty breathing
Symptoms appear 2–14 days after exposure

Flu

Fever
Cough
Body aches
Fatigue and weakness
Sore throat
Congestion
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Allergies

Sneezing
Itchy eyes and nose
Runny or stuffy nose
Watery, red, or swollen eyes
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Recommendations for cancer patients.
Patients with hematologic and oncologic malignancies on active treatment should practice universal precautions recommended by the
CDC:
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•

Social distancing by avoiding crowds (especially in poorly ventilated spaces) and minimize public transportation as much as
possible.

•

Wash your hands often with soap and water for at least 20 seconds (especially after blowing your nose, coughing, sneezing, or
having been in a public place).

•

Avoid touching your face, nose, or eyes.

•

Use hand sanitizer that contains at least 60% alcohol if soap and water are not available.

•

Avoid touching surfaces in public such as elevator buttons, door handles, handrails, and handshaking with people. Can use a
tissue or your sleeve to cover your hands or fingers if you must touch something.

•

Practice routine cleaning and disinfecting of frequently touched surfaces in your home (example: tables, doorknobs, light
switches, handles, desks, toilets, faucets, sinks, and cell phones).

•

Avoid any sick contacts or family members.

•

Watch out for the following symptoms and emergency warning signs:

•

Difficulty breathing or shortness of breath.

•

New confusion or inability to arouse.

•

Bluish lips or face.
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•

Temperature above 100.4 F with a low neutrophil count (commonly seen in patients with hematologic malignancies and on
active chemotherapy).

•

Consult your healthcare provider for any questions or to discuss your symptoms.
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Recommended precautions for cancer centers.
Patients that are symptomatic and have traveled to endemic areas (within 14 days) should be masked and isolated immediately
Patients that are without symptoms and have traveled to endemic areas (within 14 days) should be masked, isolated, and assessed.
Patients with symptoms and no known travel/exposure: avoid coming to the cancer center and can be screened over the phone:
If patient has fever + cough and clinically stable: can get respiratory viral panel (RVP) testing at an urgent care center. If RVP negative, then
pursue COVID testing
If fever + cough and clinically unstable: should go to the emergency room
Dispose of all magazines in the lobby and books in the treatment room and education area
Remove all courtesy telephones
No snacks or coffee openly available for self-service. They can be handed out by a staff member as requested. Wearing gloves should be
recommended for any staff member distributing snacks.
There should be a designated isolation room and adjacent bathroom for any patient that needs to be isolated.
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Gowns, gloves, and masks should be available for clinical teams at designated locations, especially in BMT and leukemia treatment units.
Health care providers who will be performing assessments of suspected cases should have had N-95 fit testing.
Injections that can be given without exposing patients to infusion:
•

Octreotide

•

Lanreotide

•

Erythropoietin stimulating agents

•

Growth factors

Author Manuscript
Author Manuscript
Cancer Med J. Author manuscript; available in PMC 2020 May 13.

Patel et al.

Page 11

Table 4:

Author Manuscript

Priority classification of cancer patients.
Priority A: Patients who are deemed critical and require urgent services/treatment even in the event of a pandemic due to instability, unbearable
suffering and/or immediate life-threatening disease. The list below is not limited to these situations.
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•

Rapidly progressing tumors such as brain, acute leukemia, aggressive lymphomas, cervical cancers, anal cancers and most head
and neck cancers require assessment, with priority for ambulatory radiation or chemotherapy if their cancer is potentially curable.

•

Spinal cord compression requiring emergency MRI and radiation oncology consultation and ongoing symptom management.

•

SVC syndrome, requiring radiation oncology consultation.

•

Acute pain crisis requiring assessment and pain control.

•

New onset, acute delirium.

•

Acute, new onset or progressive dyspnea requiring radiation, chest tube drainage, palliative chemotherapy.

•

Malignant bowel obstruction or bowel perforation which may need radiation and surgical oncology services.

•

Metabolic crisis assessment and care for hypo- and hypercalemia.

•

Pathologic fractures requiring orthopedic assessment, radiation oncology and pain management.

Priority B: Patients who require services/treatment, including supportive care, psychosocial care and toxicity management but deemed noncritical as patient is stable without unbearable suffering and no immediate life-threatening situation. The majority of patients requiring
chemotherapy will be priority B.
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•

IV medications/electrolyte supplementation not part of systemic treatment.

•

For patients starting therapy, recognizing that there are little to no data supporting long delays, this will be a judgment call for
each patient.

•

Patients already receiving therapy will need to be assessed as to whether they require ongoing treatment and if it can possibly
wait weeks before continuing treatment.

Priority C: Patients who are generally healthy whose condition is non-life threatening where services/treatments can be delayed without
anticipated change in outcome.
•

Patients receiving oral hormone therapy, especially in the adjuvant setting.

•

Patients receiving follow up care.

•

Patients receiving IV bisphosphonates if that is the only IV treatment required.
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